Welichem completes Phase IIa Clinical Trial on Eczema



    BURNABY, BC, June 19 /CNW/ - Welichem Biotech Inc. (the "Company")
(TSX- V: WBI), a biotechnology company developing therapeutic drugs for the
treatment of anti-inflammatory and auto-immune diseases and cancer, is pleased
to announce that the clinical component of a Phase IIa trial on Atopic
Dermatitis (a form of eczema) has been completed. The final report on this
randomized, double-blinded, vehicle-controlled study to evaluate the safety,
tolerability and efficacy of topically applied WBI-1001 cream in subjects with
Atopic Dermatitis (AD) is expected later this summer.
    Atopic Dermatitis is a chronic, inflammatory condition that causes the
skin to become inflamed, cracked and itchy. It occurs worldwide, its
prevalence is increasing and in North America it affects over 15 million
people. The condition is especially prevalent in young children. Current
therapeutic treatments have variable efficacy and often undesirable side
effects.
    The Company has initiated plans for a Phase IIb clinical trial to further
evaluate the properties of WBI-1001 as a topical cream application against AD.

    ON BEHALF OF THE BOARD
    York Yingping Guo
    President and Chief Executive Officer

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of the content of this news
    release. This press release contains forward-looking statements that
    include our belief as to the potential of our products. Certain risks and
    uncertainties such as our ability to successfully commercialize the
    products could cause the Company's actual results to differ materially
    from those in the forward-looking statements. The Company thus seeks safe
    harbour.

    %SEDAR: 00021386E




For further information:

For further information: York Yingping Guo, Tel.: (604) 432-1703, Email:
yorkguo@welichem.com; Yan Chen, Business Development Manager, Tel.: (604)
432-1703, Email: investors@welichem.com

Organization Profile

Welichem Biotech Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890